ES2194129T3 - Compuestos farmaceuticos. - Google Patents

Compuestos farmaceuticos.

Info

Publication number
ES2194129T3
ES2194129T3 ES96945283T ES96945283T ES2194129T3 ES 2194129 T3 ES2194129 T3 ES 2194129T3 ES 96945283 T ES96945283 T ES 96945283T ES 96945283 T ES96945283 T ES 96945283T ES 2194129 T3 ES2194129 T3 ES 2194129T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compounds
compounds
new
cryptophine
cryptoficine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96945283T
Other languages
English (en)
Inventor
Chuan Shih
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hawaii at Manoa
Wayne State University
University of Hawaii at Hilo
Original Assignee
University of Hawaii at Manoa
Wayne State University
University of Hawaii at Hilo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Hawaii at Manoa, Wayne State University, University of Hawaii at Hilo filed Critical University of Hawaii at Manoa
Application granted granted Critical
Publication of ES2194129T3 publication Critical patent/ES2194129T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA INVENCION DESCRIBE NUEVOS COMPUESTOS DE CRIPTOFICINA QUE PUEDEN RESULTAR UTILES PARA INTERRUMPIR EL SISTEMA DE MICROTUBULINA, COMO AGENTES ANTINEOPLASICOS Y PARA EL TRATAMIENTO DEL CANCER. LA INVENCION INCLUYE ADEMAS UN FORMULADO PARA ADMINISTRAR LOS NUEVOS COMPUESTOS DE CRIPTOFICINA.
ES96945283T 1995-12-22 1996-12-20 Compuestos farmaceuticos. Expired - Lifetime ES2194129T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US914595P 1995-12-22 1995-12-22
US2507996P 1996-08-30 1996-08-30

Publications (1)

Publication Number Publication Date
ES2194129T3 true ES2194129T3 (es) 2003-11-16

Family

ID=26679113

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96945283T Expired - Lifetime ES2194129T3 (es) 1995-12-22 1996-12-20 Compuestos farmaceuticos.

Country Status (8)

Country Link
EP (1) EP0869786B1 (es)
JP (1) JP2000502351A (es)
AT (1) ATE233745T1 (es)
AU (1) AU1469097A (es)
CA (1) CA2241086A1 (es)
DE (1) DE69626544T2 (es)
ES (1) ES2194129T3 (es)
WO (1) WO1997023211A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264063C (en) * 1996-08-30 2007-03-13 Eli Lilly And Company Cryptophycin compounds
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
CA2281107A1 (en) * 1997-02-26 1998-09-03 Eli Lilly And Company Tripeptide and tetrapeptide pharmaceutical compounds
US6143909A (en) * 1997-02-26 2000-11-07 Eli Lilly And Company Selective epoxidation process for preparing pharmaceutical compounds
EP0870506A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116954A (en) * 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
GB8814813D0 (en) * 1988-06-22 1988-07-27 Beecham Group Plc Novel compounds
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US4845085A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
CA2179490A1 (en) * 1993-12-21 1995-06-29 Trimurtulu Golakoti New cryptophycins
EP0850057A4 (en) * 1995-08-30 2001-04-11 Lilly Co Eli Pharmaceutical compounds
JP2001502297A (ja) * 1996-08-30 2001-02-20 イーライ・リリー・アンド・カンパニー 医薬用化合物
CA2264297A1 (en) * 1996-08-30 1998-03-05 Chuan Shih Pharmaceutical compounds

Also Published As

Publication number Publication date
DE69626544D1 (de) 2003-04-10
EP0869786A4 (en) 1999-04-14
AU1469097A (en) 1997-07-17
DE69626544T2 (de) 2004-01-15
CA2241086A1 (en) 1997-07-03
ATE233745T1 (de) 2003-03-15
WO1997023211A1 (en) 1997-07-03
EP0869786B1 (en) 2003-03-05
EP0869786A1 (en) 1998-10-14
JP2000502351A (ja) 2000-02-29

Similar Documents

Publication Publication Date Title
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
MX9305934A (es) Nuevo modificador de resistencia a drogas multiples.
ES2176197T3 (es) Sistema de administracion transdermal que contiene un acido acetilsalicilico para la terapia de trombosis y la profilaxis del cancer.
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2114056T3 (es) Uso de derivados nor y homo de acidos biliares como potenciadores de absorcion para medicamentos.
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
SV1998000029A (es) Compuestos de pirazina ref. pg3186
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2165441T3 (es) Inhibidores de calpaina y/o catepsina b oxazolidin sustituidos.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
ES2181130T3 (es) Antagonistas quinazolin-4-ona del ampa.
ES2098140T3 (es) Liosferas que contienen gonadotropina.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
EA199900246A1 (ru) Фармацевтические соединения
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
MX9704490A (es) Tratamiento terapeutico combinado de las patologias hiperproliferativas.